Комплексная иммунологическая и молекулярная диагностика пацилломавирусной инфекции у больных и определение формирования злокачественной трансформации эпителиальных тканей
Диссертация
Высокая контагиозность вируса и половой путь передачи способствуют его широкому распространению среди различных групп населения, в особенности сексуально активных лиц. С точки зрения эпидемиологии к факторам риска развития РШМ и состояний, ему предшествующих, относятся: раннее начало половой жизни, высокая сексуальная активность, частая смена половых партнеров, несоблюдение половой гигиеиы… Читать ещё >
Список литературы
- Александрова Ю. Н. Лыщев A.A., Сафронников Н. Р. и др. Папилломавирусная инфекцияу здоровых женщин Санкт-Петербурга // Вопросы онкологии. 2000. — Т. 46, № 2. -С. 75−179.
- Аполихина И.А. Папилломавирусная инфекция гениталий у женщин / Под ред. В.И.
- Кулакова. М.: Гэотар-мед, 2002. — 111 с.
- Бохман Я.В., Лютра У. К. Рак шейки матки. Кишинев: Штиинца, 1991.
- Ващенко С.Н. Частота выявления возбудителей урогенитальной инфекции методомполимеразной цепной реакции у женщин, проживающих в Приморском крае // Генодиагностика в практической медицине Дальнего Востока: Материалы конфер. -Владивосток, 2000.
- Вишневский A.C., Сафронникова Н. Р. 2002. Дискуссионные вопросы леченияпапилломавирусной инфекции шейки матки. Практическая онкология. 3(3): 166−172.
- Голованова В.А., Новик В. И., Гуркин Ю. А. Частота и факторы рискапапилломавирусной инфекции и дисплазии эпителия шейки матки у сексуально-активных девушек-подростков. Вопр. онкол. 1999. Т. 45, № 6. — С. 623−626.
- Головина Л.И. Кольпоскопическая и цитологическая оценка плоских кондилом и ихсвязи с интраэпителиальной неоплазией шейки матки: Дисс. канд. мед. наук СПб. -1994.
- Дебабов В.Г. ДНК-вакцинация и генотерапия на основе транзиентной экспрессиинуклеиновых кислот в соматическихх клетках человека и животных // Молекулярная биология. 1997. -№ 31.-С. 209−215.
- Иглесиас-Кортит Л., Иглесиас Г. Д. Инфекции половых органов и неопластическиеизменения шейки матки // В сб.: Репродуктивное здоровье. Т.2. Редкие инфекции: Медицина. — 1988. — С. 390−402.
- Катханова O.A. Клинико-эпидемиологические аспекты папилломавирусной инфекции:этиология, патогенез, клиника, диагностика: Дисс.. канд. биол. наук. М., 2003.
- Киселев Ф.Л. Вирус-ассоциированные опухоли человека: рак шейки матки и вирусыпапиллом // Биохимия. 2000. — Т. 65, № 1. — С. 79−91.
- Киселев Ф.Л., Павлиш O.A., Татосян А. Г. Молекулярные основы канцерогенеза учеловека.- М., 1990. с.64
- Коломиец Л.А., Уразова Л. Н., Севастьянова Н. В., Чуруксаева О. Н. Клиникоморфологические аспекты цервикальной папилломавирусной инфекции // Вопр. онкол. 2002.-Т. 48, № 1.-С. 43−46.
- Костава М.Н. Криодеструкция и диатермокоагуляция доброкачественных заболеванийшейки матки // Заболевания шейки матки: Клин, лекции. М., 1997. — С. 58−62.
- Краснопольский В.И., Радзинский В. Е., Буянова С. Н., Манухин И. Б., Кондриков Н.И.
- Патология влагалища и шейки матки. М.: Медицина, 1997. С. 28−35.
- Манухин И.Б., Минкина Г. Н., Пинегин Б. В. Иммунотерапия папилломавируснойинфекции шейки матки // Акуш. и гин. 1998. — № 3. — С. 24−26.
- Новик В.И. Эпидемиология рака шейки матки, факторы риска, скрининг // Практич. онкол 2002. -Т. 3,№ 3. — С. 156−164.
- Прилепская В.Н. Возрастные особенности шейки матки. Современные методыдиагностики патологии шейки матки // Акуш. и гин. 1998. — № 6. — С. 51−4.
- Прилепская В.Н., Кондриков Н. И., Бебнева Т. Н. Значение вируса папилломы человекав развитии диспластических процессов шейки матки // Гинекол. 2000/ - Т. 2, № 3. -С.80−82.
- Прилепская В.Н., Роговская С. И., Межевитинова Е. А. Кольпоскопия: Практ. рук. М., 1997.- 108 с.
- Прилепская В.Н., Рудакова Е. Б. Эрозии и псевдоэрозии шейки матки.// Заболеванияшейки матки, влагалища и вульвы/ под ред. В. Н. Прилепской. М., 1999. — С. 66−75.
- Роговская С.И. Папилломавирусная инфекция гениталий. Клиника и лечение.
- Заболевания шейки матки: Клин, лекции / под ред. В. Н. Прилепской. М., 1997. — С. 46−51.
- Скрипкиин Ю.К. Опыт применения кондилина в лечении остроконечных кондилом //
- ЗППП.- 1995.-№ 5.-С. 17−19.
- Т.Н.Бебнева, В. Н. Прилепская. Папилломавирусная инфекция и патология шейки матки.- Гинекол. 2001. — Т. 3, № 3. — С. 2−7.
- Хансон К.П., Имянитов Е. Н. Современные представления о канцерогенезе рака шейкиматки // Практич. онкол. 2002. — Т. 3, № 3. — С. 145−155.
- Яковлева И.А., Кукутэ Б. Г. Классификация предрака и рака шейки матки // Арх. патол.1977.-Т. 39, № 1.-С. 18−25.
- Alani R.M., Munger К. Human papillomaviruses and asscociated malignancies // J. Clin.
- Oncol. 1998. — № 16. — P. — 330−337.
- Alter B. J., Grillot-Courvalin C., Bach M. L. et al. Secondary cell-mediated lympholysis: importance of H-2 LD and SD factors // J. Exp. Med. 1976. — № 143. — P. — 1005−1014.
- Alvarez-Salas L.M., Cullinan A.E., Siwkowski A. et al. Inhibition of HPV-16 E6/E7immortalization of normal keratinocytes by hairpin ribozymes // Proc. Natl. Acad. Sci. U S A.- 1998.-№ 95. -P.- 1189−1194.
- Arany I., Rady P., Tyring S.K. Alterations in cytokine/antioncogene expression in skin lesionscaused by «low risk» types of human papillomaviruses // Viral. Immunol. 1993. — № 16. -P. — 255−265.
- Arany I., Goel A., Tyring S. K. Interferon response depends on viral transcription in humanpapillomavirus-containing lesions // Anticancer Res. 1995. — № 15. — P. — 2865−2869.
- Arany 1., Rady P., Tyring S. K. Effect of interferon therapy on human papillomavirus copynumber in patients with condyloma acumina-tum // Am. J. Med. Sci. 1995. — № 310. — P. -14−18.
- Aynaud O., Piron D., Barrasso R., Poveda J. D. Comparison of clinical, histological, andvirological symptoms of HPV in H1V-1 infected men and immunocompetent subjects // Sex. Transm. Infect. 1998. — № 74. — P. — 32−34.
- Baker T. S., Newcomb W. W., Olson N. H. et al. Structures of bovine and humanpapillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction // Biophys. J. 1991. — № 60. — P. — 1445−1456.
- Barker J. N., Mitra R. S., Griffiths C. E. et al. Keratinocytes as initiators of inflammation //1.ncet. 1991. -№ 337. — p. — 211−214.
- Barnard P., McMillan N. A. The human papillomavirus E7 oncoprotein abrogates signalingmediated by interferon-alpha//Virol. 1999. -№ 259. — P. — 305−313.
- Beckman G., Birgander R., Sjalander A. et al. Is p53 polymorphism maintained by naturalselection? // Human Heredity. 1994. — № 44. — P. — 266−270.
- Beer-Romero P., Glass S., Rolfe M. Antisense targeting of E6AP elevates p53 in HPVinfected cells but not in normal cells // Oncogene. 1997. — № 14. — P. — 595−602.
- Bernard B.A., Bailly C., Lenoir M.C. et al. The human papillomavirus type 18 (HPV 18) E2gene product is a repressor of the HPV 18 regulatory region in human keratinocytes // J. Virol. 1989.-№ 63.-P.-4317−4324.
- Billich A. HPV vaccine Medlmmune/GlaxoSmithKline // Curr. Opin. Investig. Drugs.2003.- № 4.-P.-210−213.
- Bontkes, H. J., de Gruijl T. D.,. Walboomers J. M. et al. Assessment of cytotoxic Tlymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions// Br. J. Cancer. 1997. -№ 76. — P. — 1353−1360.
- Bontkes, H. J., Van Duin M., DeGruijl T. D. et al. HPV-16 infection and progression ofcervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV-16 E6 sequence variants // International Journal of Cancer. 1998. — № 78. — P. — 166−171
- Boom R., Sol C.J., Salimans M.M. et al. Rapid and simple method for purification of nucleicacids //
- J. Clin Microbiol. 1990. — № 28. — P. — 495−503.
- Borg H., Medley G., Garland S. Polymerase chain reaction. A sensitive indicator of theprevalence of human papillomavirus DNA in population with sexually transmitted disease // 39. P. — 654−658
- Bosch F.X., Lorincz A., Munoz N. et al. The casual relation between human papillomavirusand cervical cancer // J. Clin. Pathol. 2002. — № 55. — P. — 244−265.
- Bosch F.X., Manos M.M., Munoz N. et al. Prevalence of human papillomavirus in cervicalcancer: a worldwide perspective // J. Natl. Cancer Inst. 1995. — 87. — P. — 796−802.
- Bouvard V., Storey A., Pim D., Banks L. Characterization of the human papillomavirus E2protein: evidence of trans-activation and trans-repression in cervical keratinocytes // EMBO J. 1994.-№ 13.-P.-5451−5459.
- Braun, L., Durst M., Mikumo R., Gruppuso P. Differential response of nontumorigenic andtumorigenic human papillomavirus type 16-positive epithelial cells to transforming growth factor beta 1 // Cancer Res. 1990. — № 50. — P. — 7324−7332.
- Brown D.R., Legge D., Qadadri B. Distribution of human papillomavirus types incervicovaginal washings from women evaluated in a sexually transmitted diseases clinic // Sex. Transm. Dis. 2002. — № 29. — P. — 763−768.
- Bubenik J. Therapeutic vaccines against HPV16-associated tumors // Minireview. Neoplasma.2002. № 49. — P. — 285−289.
- Burd E.M. Human papillomavirus and cervical cancer // Clin. Microbiol. Rev. 2003. — № 16.-P. 1−17.
- Burkman R.T. Oral contraceptives: an update // Drugs Today (Bare). 1999. — № 35. — P.857.866.
- Chang Y.E., Pena L., Sen G.C. et al. Long-term effect of interferon on keratinocytes thatmaintain human papillomavirus type 31 // J. Virol. 2002. — № 76. — P. — 8864−8874.
- Cho C.W., Poo H., Cho Y.S. et al. HPV E6 antisense induces apoptosis in CaSki cells viasuppression of E6 splicing // Exp. Mol. Med. 2002. — № 34. — P. — 159−166.
- Cho N.H., Kim Y.T., Kim J.W. Alteration of cell cycle in cervical tumor associated withhuman papillomavirus: cyclin-dependent kinase inhibitors //Yonsei Med. J. 2002. — № 43. -P. — 722−728.
- Chua K. L., Hjerpe A. Persistence of human papillomavirus (HPV) infections precedingcervical carcinoma // Cancer. 1996. -№ 77. — P. — 121−127.
- Claus E.B., Stowe M., Carter D. Oral contraceptives and the risk of ductal breast carcinoma insitu // Breast Cancer Res. Treat. 2003. — № 81. — P. — 129−136.
- Clavel C., Rihet S., Masure M. et al. DNA-EIA to detect high and low risk HPV genotypes incervical lesions with T6/T7 primer mediated multiplex PCR // 1998.
- Clerici M., Merola M., Ferrario E. et al. Cytokine production patterns in cervicalintraepithelial neoplasia: association with human papillomavirus infection // J. Natl. Cancer Inst. 1997. — № 89. — P. — 245−250.
- Cooper B., Schneider S., Bohl J. et al. Requirement of e6ap and the features of humanpapillomavirus e6 necessary to support degradation of p53 // Virology. 2003. — № 306. — P.- 87−99.
- Cope J., Hildesheim A., Schiffman M. et al. Comprasion of the hybrid capture tube test and
- PCR for detection of human papillomavirus DNA in cervical specimens // J. Clin Microbiol.- 1997. № 35. — P. — 2262−2265.
- Coutlee F., Mayrand M.H., Provencher D. The future of HPV testing in clinical laboratoriesand applied virology research // J. CI & Diagn. Virol. 1997. — № 8. — P. — 123−41.
- Cripe T.P., Alderborn A., Anderson R.D. et al. Transcriptional activation of the humanpapillomavirus-16 P97 promoter by an 88-nucleotide enhancer containing distinct cell-dependent and AP-1-responsive modules // New Biol. 1990. — № 2. — P. — 450−463.
- Critchlow C.W., Koutsky L.A. Epidemiology of human papillomavirus infection // Genitalwarts. Human papillomavirus infection / Ed. A.Mindel. London: Edward Arnold, 1995. — P. -53−81.
- Critchlow C. W, Koutsky L.A. Epidemiology of human papillomavirus infection // Genitalwarts. Human papillomavirus infection / Ed. A.Mindel. London: Edward Arnold, 1995. -P.-53−81.
- Critchlow C. W., Holmes K. K., Wood R. et al. Association of human immu-nodeficiencyvirus and anal human papillomavirus infection among homo-sexual men // Arch. Intern. Med. 1992. — № 152. — P. — 1673−1676.
- Critchlow C. W., Hawes S. E., Kuypers J. M. et al. Effect of HIV infection on the naturalhistory of anal human papillomavirus infection //AIDS. 1998. — № 12. — P. — 1177- 1184.
- Cubie H. A., Norval M., Crawford L. et al. Lymphoproliferative response to fusion proteins ofhuman papillomaviruses in patients with cervical intraepithelial neoplasia // Epidemiol. Infect. 1989. — № 103. — P. — 625−632.
- Cullen A. P., Reid R., Campion M., Lorincz A. T. Analysis of the physical state of differenthuman papillomavirus DNAs in intraepithelial and invasive cervical neoplasms // J. Virol. -1991. -№ 65. P. — 606−612.
- Cullen A.P., Reid R., Campion M., Lorincz A.T. Analysis of the physical state of differenthuman papilomavirus DNAs in intraepithelian and invasive cervical neoplasms // J.Virol. -1991.- 65.-P.-606−612.
- Cuschieri K.S., Seagar A.L., Moore C. et al. Development of an automated extractionprocedure for detection of human papillomavirus DNA in liquid based cytology samples // J. Virol Methods. 2003. — Vol. 107, № 1. — P. — 107−13.
- Dahl M.V. Imiquimod: a cytokine inducer // J. Am. Acad. Dermatol. 2002. — Vol. 47, № 4.1. P. 205−208.
- Dallner J. Antibody responses to defined HPV epitopes in cervical neoplasia // Papillomavirus1. Rep. 1994.-№ 5.-p.-35−41.
- Danos O., Katinka M., Yaniv M. Human papillomavirus la complete DNA sequence: a noveltype of genome organization among papovaviridae // EMBO J. 1982. — № 1. — P. — 231−236.
- Das B. C., Sharma J. K., Gopalakrishna V., Luthra U. K. Papillomavirus type 16 DNA incervical preneoplastic and neoplastic lesions // J. Gen. Virol. 1992. — № 73. — P. — 23 272 336.
- Das B.C., Sharma J.K., Gopalakrishna V., Luthra U.K. Papillomavirus type 16 DNA incervical preneoplastic and neoplastic lesions // J.Gen.Virol. 1992. — № 73. — P. — 2327−2336.
- De Marco, F., and Marcante M. L. Cellular and molecular analyses of interferon betacytopathic effect on HPV-16 in vitro transformed human keratinocytes (HPK-IA) // J. Biol. Regul. Homeost. Agents/- 1995.-№ 9.-P. -24−30.
- De Sanjose S., Santamaria M., Alonso de Ruiz P. et al. HPV types in women with normalcervical cytology // The epidemiology of cervical and human papillomavirus / Eds N. Munos, F.X.Bosch, K.V. Shan, A. Meheus Lyon, France: IARC, 1992. — P. — 75−84.
- De Villiers E.M. Human pathogenic papillomavirus types: an update // Human pathogenicpapillomaviruses, Topics in Microbiology and Immunology / Eds H. zur Hausen. Berlin, 1994, — № 186.-P. — 1−13.
- De Wolf CJM. Organization and Results of Cervical Canser Screening in Europe over the Past
- Years //New Developments in Cervical Cancer Screening and prevention / Eds E. Franco & J. Mosonego. Oxford: Blackwell Science. — 1997. — P. — 209−19.
- De Franco A. L. Molecular aspects of B-lymphocyte activation // Annu. Rev. Cell Biol.1987. № 3. — P. — 143−178.
- Dolei A., Curreli S., Marongiu P. et al. Human immunodeficiency virus infection in vitroactivates naturally integrated human papillomavirus type 18 and induces synthesis of the LI capsid protein // J. Gen. Virol. 1999. — № 80. — P. — 2937−2944.
- Duensing S., Duensing A., Crum C.P., Munger K. Human papillomavirus type 16 E7oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype // Cancer Res. 2001. — № 61. — P. — 2356−2360.
- Dupuy C., Buzoni-Gatel D., Touze A. et al. Cell mediated immunity induced in mice by HPV
- LI virus-like particles//Microb. Pathog. 1997.-№ 22. -P. -219−225.
- Durst M., Kleinheinz A. Hotz M., Gissman L. The physical state of human papillomavirustype 16 DNA in benign and malignant genital tumours // J. Gen. Virol. 1985.-№ 66.-P. — 1515−1522.
- Dyson N., Howley P.M., Munger K., Harlow E. The human papillomavirus 16 E7 oncoproteinis able to bind to the retinoblastoma gene product // Science. 1989. — № 243. — P. — 934−937.
- Elfgren K., Jacobs M., Walboomers J.M. et al. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia // Obstet. Gynecol. 2002. — Vol. 100 (5 Pt 1). -P.-965−971.
- Emeny R.T., Wheeler C.M., Jansen K.U. et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine // J. Virol. 2002. — № 76. — P. — 7832−7842.
- Evander M., Edlund K., Gustafsson A. et al. Human papillomavirus infection is transient in young women: a population-based cohort study //J. Infect. Dis. 1995. — 171. — P. — 10 261 030.
- Evans E. M., Man S., Evans A. S., Borysiewicz L. K. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes // Cancer Res. 1997. — № 57. — P. -2943−2950.
- Fausch S.C., Da Silva D.M., Eiben G. L et al. Hpv protein/peptide vaccines: from animal models to clinical trials//Front. Biosci. 2003. -№ 8. — P. — 81−91.
- Favre N., Bordmann G., Rudin W. Comprasion of cytokine measurements using ELISA, ELISPORT and semi-quantative RT-PCR // J.Immunol. Methods. 1997. — № 204. — P. -57−66.
- Feltkamp M. C., Smits H. L., Vierboom M. P., Minnaar R. P., de Jongh B. M., Drijfhout J. W., ter Schegget J., Melief C. J., and Kast W. M. 1993.
- Ferenczy A., Franco E., Arseneau J. et al. Diagnostic perfomance of Hybrid Capture human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytologic study // Am. J. Obstet. Gynecol. 1996. — № 175. — P. — 651.
- Ferrera A., Velema J.P., Figueroa M. et al. Human papillomavirus infection, cervical dysplasia and invasive cervical cancer in Honduras: a case-control study // Int. J. Cancer. 1999. — № 82. — P. — 799−803.
- Franco E. L., Duarte-Franco E., Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection//CMAJ. -2001.-№ 164.-P.- 1017−1025.
- Franco E.L., Rohan T.E., Villa L.L. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer //. J. Natl. Natl. Cancer Inst. 1999. — № 91.-P.-506−511.
- Franco E. L., Villa L. L., Richardson H. et al. Epidemiology of Cervical Human Papillomavirus Infection // New Developments in Cervical Cancer Screening and prevention /Eds Franco E. & Mosonego J. Oxford: Blackwell Science. 1997:14−22.
- Franco E., Villa L., Sobrinho J. et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from high-risk area for cervical cancer // J. Infect. Dis. 1999.-№ 180.-P. — 1415−1423.
- Frazer I. Vaccines for papillomavirus infection // Virus Res. 2002. — № 89. — P. — 271−274.
- Garland S.M. Human papillomavirus update with a particular focus on cervical disease // Patology. 2002. — № 34. — P.- 213−224.
- Gasco M., Crook T. The p53 network in head and neck cancer // Oral. Oncol. 2003. — № 39. -P.-222−231.
- Gill D. K., Bible J. M, Biswas C. et al. Proliferative T-cell responses to human papillomavirus type E5 are decreased amongst women with high-grade neoplasia // J. Gen. Virol. 1998. -№ 79.-P.-1971−1976.
- Glasebrook A. L., Fitch F. W. T-cell lines which cooperate in generation of specific cytolytic activity // Nature. 1979. — № 278. — P. — 71−173.
- Gravitt P., Hakenewerth A., Stoerker J. A direct comprasion of methods proposed for use in widespread screening of human papillomavirus infections/ Mo. l cell, probes. 1991. — № 5. — P. — 65−72.
- Greenberg P. D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells // Adv. Immunol. 1991. — № 49. — P. — 281−355.
- Gross GE. & Barrasso R. Humman Papilloma Virus Infection. A Clinical Atlas. 1997. -c.144
- Grossman S.R., Laimins L.A. E6 protein of human papillomavirus type 18 binds zinc // Oncogene. 1989. — № 9. — P. — 1089−1093.
- Gunter J. Genital and perianal warts: new treatment opportunities for human papillomavirus infection // Am. J. Obstet. Gynecol. 2003. — № 189(3 Suppl). — P. — 3−11.
- Hart K., Williams O., Thelwell N. et al. Novel method for detect for detection, typing and quantitation of human papillomaviruses in clinical samples // J. Clin. Microbiol. 2001. — № 39.-P.-3204−3212
- Hatch K.D., Schneider A., Abdel-Nour M.W. An evaluation of human papillomavirus testing for intermediate- and high-risk types as triage before colposcopy // Am. J. Obstet. Gynecol. -1995.-№ 172.-P. 1150.
- Hawley-Nelson P., Vousden K.H., Hubbert N.L. et al. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes // EMBO J.- 1989. №. — P. — 3905−3910.
- Hengge U.R., Benninghoff B., Ruzicka T., Goos M. Topical immunomodulators—progress towards treating inflammation, infection, and cancer // Lancet Infect. Dis.- 2001. № 1. — P. — 189−198.
- Herrington C.S. Human papillomaviruses and cervical neoplasia. Classification, virology, pathology and epidemiology // J. Clin. Pathol. 1994. — № 47. — P. — 1066−1072.
- Hildesheim, A., Schiffman M. H, Gravitt P. E. et al. Persistence of type-specific human papillomavirus infection among cytologically normal women // J. Infect. Dis. 1994. — № 169.-P.-235−240.
- Hillemanns, P., T. V. Ellerbrock, S. McPhillips, P. Dole, S. Alperstein, D.
- HIV and human papillomavirus as independent risk factors for cervical neoplasia in women with high or low numbers of sex partners // Sex. Transm. Infect. № 75. — P. — 258−260.
- Ho G. Y., Bierman R., Beardsley L. et al. Natural history of cervicovaginal papillomavirus infection in young women // N. Engl. J. Med. 1998. — № 338. — P. — 423128.
- Hodi F.S., Dranoff G. Genetically modified tumor cell vaccines // Surg. Oncol. Clin. N. Amer. 1998.-№ 7. -P. -471−485.
- Hubbard R.A. Human papillomavirus testing methods // Arch. Pathol. Lab. Med. 2003. — № 127.-P.-940−945.
- Hubbert N.L., Sedman S.A., Schiller J.T. Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes // J. Virol. 1992. — Vol. 66, № 10. — P. -6237−6241.
- IARC Monographs on the evaluation of carcinogenic risks to humans // Human papillomaviruses. Lyon: IARC. — 1995. — P. — 64.
- Jablonska S. Traditional therapies for the treatment of condylomata acuminata (genital warts) // Australas. J. Dermatol. 1998. — № 39 (Suppl 1). — P. — 2−4.
- Jackson S., Harwood C., Thomas M. et al. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins // Genes. Dev. 2000. — № 14. — P. — 3065−3073.
- Jenkins D. Diagnosing human papillomaviruses: recent advances // Curr. Opin. Infect. Dis. -2001.- № 14. P. — 53−62.
- Jensen S.L. Comparison of podophyllin application with simple surgical excision in clearance of perianal condylomata acuminatum // Lancet. 1985. — № 2. — P. — 1146−1148.
- Johnson X. W., Sun M. A., Chiasson T. C., Wright Jr. Prevalence of anal human papillomavirus infection and anal cytologic abnormalities in HIV-seropositive women // AIDS. 1996. — № 10. — P. — 1641−1647.
- Kadish A. S., Ho G. Y., Burk R. D. et al. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia //J. Natl. Cancer Inst. 1997. — № 89. — P. — 1285−1293.
- Kast W. M., Brandt R. M., Sidney J. et al. Role of HLA-A motifs in identifi-cation of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins // J. Immunol. -1994. № 152. — P. — 3904−3912.
- Khan M. A., Tolleson W. H., Gangemi J. D., Pirisi L. Inhibition of growth, transformation, and expression of human papillomavirus type 16 E7 in human keratinocytes by alpha interferons // J. Virol. 1993. — № 67. — P. — 3396−3403.
- Kitagawa K., Yoshikawa H., Onda T. et al. Genomic organization of human papillomavirus type 18 in cervical cancer specimens // Jpn. J. Cancer Res. 1996. — № 87. — P. — 263−266.
- Klencke B., Matijevic M., Urban R.G. et. al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101 // Clin. Cancer Res. -2002.-№ 8.-P. 1028−1037.
- Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections//Eur. J. Cancer. 2002. — № 38.-P.-2229−2242.
- Koutsky L. Epidemiology of genital human papillomavirus infection // Am. J. Med. 1997. -№ 102. — P. — 3−8.
- Koutsky L. A., Holmes K. K., Critchlow C. W. et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection // N. Engl. J. Med. 1992. — № 327. — P. — 1272−1278.
- Kyo S., Inoue M., Hayasaka N. et al. Regulation of early gene expression of human papillomavirus type 16 by inflammatory cytokines // Virology. 1994. — № 200. — P. — 130 139.
- Lambert P.F., Pan H., Pitot H.C. et al. Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice // Proc. Natl. Acad. Sci. USA.- 1993. № 90. — P.- 5583−5587.
- Lappin M. B., Kimber I., Norval M. 1996. The role of dendritic cells in cutaneous immunity. Arch. Dermatol. Res. 288:109−121.
- Leigh I. M., Glover M. T. Skin cancer and warts in immuno-suppressed renal transplant recipients // Recent Results Cancer Res. 1995. — № 139. — P. — 69−86.
- Li J., Sun Y., Garen A. Immunization and immunotherapy for cancers involving infection by a human papillomavirus in a mouse model // Proc. Natl. Acad. Sci. USA.- 2002. № 99. -P. — 16 232−16 236.
- Liu D.Z., Jin Y.X., Hou H. et al. Preparation and identification of activity of anti-HPV-6b/l 1E1 universal ribozyme-Rzl 198 in vitro // Asian J. Androl. 1999. — № 1. — P. — 195 201.
- Liu W.J., Gao F., Zhao K.N. et al. Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity // Virology. -2002. -№ 301.-P.-43−52.
- Lorincz A. T., Reid R., Bennett A. et al. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types // Obstet. Gynecol. 1992. — № 79. — P. — 328−337.
- Lorinez A.T., Reid R., Bennet A. et al. Human papillomavirus infection of cervix: relative risl associations of common anogenital types // Obstet.Gynecol. 1992. — 79. — P. — 328−337.
- Luxton J. C., Rose R. C., Coletart T. et al. P. Serological and T-helper cell responses to human papillomavirus type 16 LI in women with cervical dysplasia or cervical carcinoma and in healthy controls // J. Gen. Virol. 1997. — № 78. — P. — 917−923.
- Maehama T., Asato T., Kanazawa K. Prevalence of HPV infection in cervical cytology-normal womwn in Okinawa, Japan, as determined by polymerase chain reaction // Int. J. Gynecol. Obstet. 2000. — № 69. — P. — 175−176.
- Malejczyk M., Jozwiak J., Osiecka A. et al. Serum levels of soluble tumor-necrosis-factor receptors in patients with benign and malignant HPV-associated anogenital lesions// Int. J. Cancer. 1997. — № 73. — P. — 16−19.
- Matlashewski G., Schneider J., Banks L. et al. Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells // EMBO J. 1987. — № 6. — P. -1741−1746.
- Matsura Y., Kawagoe T., Toki N. et al. Cervical intraepithelial neoplasia (low grade) and human papillomavirus infection in cases with long-term follow-up // Acta Cytol- 1998. № 42. — P. — 625−630.
- McCree D.H., Leichliter J.S., Hogben M., St Lawrence J.S. National survey by specialty of U.S. physicians' HPV screening practices // Prev. Med. 2003. — № 36. — P. — 159−163.
- McMurray H.R., Nguyen D., Westbrook T.F., McAnce D.J. Biology of human papillomaviruses // Int. J. Exp. Pathol. 2001. — № 82. — P. — 15−33.
- Mellin H., Dahlgren L., Munck-Wikland E. et al. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer // Int. J. Cancer.- 2002. Vol. 10, № 102(2). — P. — 152−8
- Memar O. M., Arany I., Tyring S. K. Skin-associated lymphoid tissue in human immunodeficiency virus-1, human papillomavirus, and herpes simplex virus infections // J. Investig. Dermatol. 1995. — № 105. — P. — 99−104.
- Meschede W., Zumbach K., Braspenning J., et al. Antibodies against early proteins of huma papillomaviruses as diagnostic markers for invasiv cervical canser // J. Clin. Microbiol. -1998/-№ 36.-P.-475−80.
- Miller R.A. Podophyllin // Int. J. Dermatol. 1985. — № 24. — P. — 491−498.
- Minkoff H., Feldman J., DeHovitz J. et al. A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women // Am. J. Obstet. Gynecol. 1998. — № 178. — P. — 982−986.
- Morelli A. E., Belardi G., DiPaola G. et al. Cellular subsets and epithelial ICAM-1 and HLA-DR expression in human papillomavirus infection of the vulva // Acta Derm. Venereol. -1994. № 74. — P. — 45−50.
- Morris H. H., Gatter K. C., Sykes G. et al. Langerhans' cells in human cervical epithelium: effects of wart virus infection and intraepithelial neoplasia // Br. J. Obstet. Gynaecol. 1983.- № 90. P. — 412−420.
- Moscicki A. B., Shiboski S., Broering J. et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women // J. Pediatr. 1998. — № 132. — P. — 277−284.
- Mosmann T. R., Sad S. The expanding universe of T-cell subsets: Thl, Th2 and more // Immunol Today. 1996. — № 17. — P. — 138−146.
- Mota F., Rayment N., Chong S. et al. The antigen- presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium // Clin. Exp. Immunol. 1999. — № 116. — P. — 3310.
- Mullokandov M. R., Kholodilov N. G., Atkin et al. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papillomavirus tumor status // Cancer Research. 1996. — № 56. — P. — 197−205.
- Munger K., Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res. 2002. — № 89. — P. — 213−228.
- Munoz N. Human papillomavirus and cervical cancer: epidemiological evidence // New developments in cervical cancer screening and prevention / Eds E. Franco, J. Monsonego. -Oxford: Blackwell Science, 1997. P. — 3−13.
- Munoz N., Kato I., Bosch F.X. et al. Risk factor for HPV DNA detection in middle-aged women // Sex. Transm. Dis. 1996. — № 23. — P. — 504−510.
- Palefsky J. M., Holly E. A., Ralston M. L. et al. Anal cytological abnormalities and anal HPV infection in men with Centers for Disease Control group IV HIV disease // Genitourin. Med. 1997. -№ 73. -P. — 174−180.
- Palefsky J. M., Gonzales J., Greenblatt R. M. et al. Anal intraepithelial neoplasia and anal papillomavirus infection among homosexual males with group IV HIV disease // JAMA. -1990. № 263. — P. — 2911−2916.
- Pao C. C., Lin C. Y., Yao D. S., Tseng C. J. Differential expression of cytokine genes in cervical cancer tissues // Biochem. Biophys. Res. Commun. 1995. — № 214. — P. — 11 461 151.
- Park J. S., Hwang E. S., Park S. N. et al. Physical status and expression of HPV genes in cervical cancers // Gynecol. Oncol. 1997. — № 65. — P. — 121−129.
- Parkin D.M., Pisani P., Ferlay J. Global cancer statistics//Can. Cancer J. Clin. 1999. -№ 49. — P. — 33−64.
- Penn I. Cancers of the anogenital region in renal transplant recipi-ents. Analysis of 65 cases // Cancer. 1986. — № 58. — P. — 611−616.
- Perisic Z., Popovic Lazic J., Terzic B. et al. Condylomata gigantea in anal and perianal region: surgical and CO (2) laser treatment // Arch. Gynecol. Obstet. 2003. — № 267. — P. — 263−265.
- Peyton C., SchifFman M., Lorincz et al. Comprasion of PCR and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies // J Clin Microbiol. 1998. -№ 36. — P. — 3248−3254
- Picker L. J., Singh M. K., Zdraveski Z. et al. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry // Blood. 1995. -№ 86.-P. — 1408−1419.
- Pranchev N., Katsarova M. The use of Solcoderm in acute condylomas of the vulva (preliminary report) //Akush Ginekol (Sofiia). 1991. — № 30. — P. — 71−72.
- Prussin C. Cytokine flow cytometry: understanding cytokine biology at the single-cell level // J. Clin. Immunol. 1997. — № 17. — P. — 195−204.
- Richardson H., Franco E., Pintos J. et al. Determinants of low-risk and high-risk cervical human papillomavirus infections in Montreal University students // Sex. Transm. Dis. -2000. № 27. — P. — 79−86.
- Romanczuk H., Thierry F., Howley P.M. Mutational analysis of cis elements involved in E2 modulation of human papillomavirus type 16 P97 and type 18 P105 promoters // J.Virol. -1990.-№ 64.-P. 121−129
- Sach K.V., Kessis T.D., Sach F. et al. Human papillomavirus investigation of patients with cervical intraepithelial neoplasia 3, some of whom progressed to invasive canser // Int. J. Gynecol. Pathol. 1996. — № 15. -P. — 127−30.
- Sadovnikova E., Zhu X., Collins S. M. et al. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein // Int. Immunol. 1994 — № 6. — P. — 289−296.
- Sambrook J., Fritsch E.F., Maniatis T., Molecular cloning: a laboratory manyal. 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. 1989
- Samoylova E.V., Shaikhaiev G. O., Petrov S.V. et al. HPV infection in cervical-cancer cases in Russia//Int. J. Cancer. 1995.- № 61. — P. — 337−41.
- Sauvaigo S., Teoule R, Bernard P. et al. Fast solid support detection of human papillomavirus in vitro amplified DNA using a DNP-anti DNP monoclonal antibody couple // J. Virol. Methods.- 1994.-№ 46.-P.-29−38.
- Savoca S., Nardo L.G., Rosano T.F. et al. CO (2) laser vaporization as primary therapy for human papillomavirus lesions. A prospective observational study // Acta Obstet. Gynecol. Scand. 2001. — № 80. — P. — 1121−1124.
- Scala M., Bonelli G., Gipponi M. et al. Cryosurgery plus adjuvant systemic alpha2-interferon for HPV-associated lesion //. Anticancer Res. 2002. — № 22. — P. — 1171−1176.
- Schefifner M., Romanczuk H., Munger K. et al. Function of human papillomavirus proteins // Curr. Top. Microbiol, Immunol. 1994. — № 186. — P. — 83−96.
- Schefifner M., Werness B.A., Huibregtse J.M. et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 // Cell. 1990. — № 63. — P. — 1129−1136.
- SchifTman M., Schatzkin A. Test reliability is critically important to molecular epidemiology.: an example from studies of human papillomavirus infection and cervical neoplasi // Cancer Res. 1994. — № 54. — P. — 1944−1947
- Schiffman M.H. Epidemiology of cervical human papillomavirus infection // Curr. Top. Microbiol. Immunol. 1994. — № 186. — P. — 83−96.
- Schneider A., Koutsky L. Natural history and epidemiology features of genital HPV infection. // The epidemyology of cervical and human papillomavirus / Eds. N. Munoz, F.X. Bosch, K.V. Shan, A. Meheus Lyon, France: IARC, 1992. — P. — 25−52.
- Scott, M., Stites D. P., Moscicki A. B. Thl cytokine patterns in cervical human papillomavirus infection // Clin. Diagn. Lab. Immunol. 1999. — № 6. — P. — 751−755.
- Shah K. V., Viscidi R. P., Alberg A. J. et al. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix // Cancer Epidemiol. Biomarkers Prev. -1997. № 6. — P. — 233−237.
- Sherman M.E., Lorincz A.T., Scott D.R. et. al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis // J. Natl. Cancer Inst. -2003. № 95. — P. — 46−52.
- Sherman M.E., Schiffman M.H., Strickler H., Hildeshtein A. Prospects for a prophylactic HPV vaccine: rationale and future implications for cervical cancer screening // Diagn. Cytopathol. 1998. — № is. p.. 5.9.
- Si H.X., Tsao S.W., Poon C.S. et al. Viral load of HPV in esophageal squamous cell carcinoma // Int. J. Cancer. 2003. — Vol. 103, № 4. — P. — 496−500.
- Sikorski M., Zrubek H. Long-term follow-up of patients treated with recombinant human interferon gamma for cervical intraepithelial neoplasia // Int. J. Gynaecol. Obstet. 2003. -№ 82.-P. — 179−185.
- Sillman F., Stanek A., Sedlis A. et al. The relationship between human papillomavirus and lower genital intraepithelial neoplasia in immunosuppressed women // Am. J. Obstet. Gynecol. 1984. — № 150. — P. — 300−308.
- Silverberg, E" Lubera J. Cancer statistics 1987 // CA Cancer J. Clin. 1987. — № 37. — P. — 219.
- Smahel M., Sima P., Ludvikova V. et al. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules//Vaccine. 2003. — № 21. — P. — 1125−1136.
- Sotlar K., Selinka H.C., Menton M. et al. Detction of human papillomavirus type 16 E6/E7 oncogen transcripts in dysplastic and nondysplastic cervical scrapes by nested RT-PCR // Gynecol, oncol. 1998. — Vol. 69, № 2. — P. — 114−21.
- Stadnyk A. W. Cytokine production by epithelial cells // FASEB J. 1994. — № 8. — P. — 10 411 047.
- Storey A., Thomas M., Kalita A., et al. Role of a p53 polymorphism in the development of human papillomavirusassociated cancer //Nature. 1998.- № 393. — P. — 229−234.
- Sultana H., Kigawa J., Kanamori Y. et al. Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer // Ann. Oncol. 2003. — № 14. — P. — 214 219.
- Sun X. W., Kuhn L., Ellerbrock T. V. et al. Human papillomavirus infection in women infected with the human immunodeficiency virus // N. Engl. J. Med. 1997. — № 337. — P. -1343−1349.
- Syrjanen S. M. Basic concepts and practical applications of recombinant DNA techniques in detection of human pap-illomavirus (HPV) infections // APMIS. 1990. — № 98. — P. — 95 110.
- Taichmain, L. B., LaPorta R. F. The expression of papillomaviruses in epithelial cells // The papova-viridae. Plenum / Eds N. P. Salzman. New York, N. Y, 1986. — P. 109−130.
- Tarpey I., Stacey S., Hickling J. et al. Human cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (Ap0201) motif// Immunology. 1994. — № 81. — P. — 222−227.
- Tay S. K., Jenkins D., Maddox P. et al. Subpopulations of Langerhans' cells in cervical neoplasia // Br. J. Obstet. Gynaecol. 1987. — № 94. — P. — 10−15.
- Thelwell N., Millington S., Solinas A. et al. Mode of action and application of scorpion primers to mutation detection //Nucleic. Acid. Res. 2000. — № 28. — P. — 3752−3761.
- Thomas K.K., Hughes J.P., Kuypers J.M. et al. Concurrent and sequential acquisition of different genital human papillomavirus types // J. Infect. Dis. 2000. — № 182. — P. — 10 971 102.
- Ting Y., Manos M.M. Detection and typing of genital human papillomaviruses // PCR protocols: a guide to methods and applications / Eds M. A Innis., D.H. Gelfand, J.J.Sninsky, T.J.White. San Diego: Academic Press, 1990. — P. — 356−67.
- Tjalma W.A., Weyler J.J., Bogers J.J. et al. The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer // Eur. J. Obstet. Gynecol. Reprod. Biol. 2001. — № 97. — P. — 223−230.
- Tonon S.A., Picconi M.A., Zinovich J.B. et al. Human papillomavirus cervical infection and associated risk factors in a region of Argentina with a high incidence of cervical carcinoma // Infect. Dis. Obstet. Gynecol. 1999. — № 7. — P. — 237−243.
- Tsukui T., Hildesheim A., Schiffman M. H. et al. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology // Cancer Res. 1996. — № 56. — P. — 3967−3974.
- Tsutsui T., Kumakura S., Yamamoto A. et al. Association of pi6 (lNK4a) and pRb inactivation with immortalization of human cells // Carcinogenesis. 2002. — № 23. — P. -2111−2117.
- Tyring S., Conant M., Marini M. et al. Imiquimod- an international update on therapeutic uses in dermatology // Int. J. Dermatol. 2002. — № 41. — P. — 810−816.
- Veldman T., Horikawa I., Barrett J.C., Schlegel R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein // J. Virol. 2001. — № 75. -P. — 4467−4472.
- Vernon S. D., Hart C. E., Reeves W. C., Icenogle J. P. The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription // Virus Res. 1993. — № 27. — P. — 133 145.
- Villa L. L., Vieira K. B., Pei X. F., Schlegel R. Differential effect of tumor necrosis factor on proliferation of primary human keratinocytes and cell lines containing human papillomavirus types 16 and 18 // Mol. Carcinog. 1992. — № 6. — P. — 5−9.
- Volpers C., Sapp M., Komly C.A. et al. Development of type-specific and cross-reactive serological probes for the minor capsid protein of human papillomavirus type 33 // J. Virol. -1993.-№ 67.-P. 1927−35.
- Wakabayashi M.T., Da Silva D.M., Potkul R.K., Kast W.M. Comparison of Human Papillomavirus Type 16 LI Chimeric Virus-Like Particles versus L1/L2 Chimeric VirusLike Particles in Tumor Prevention // lntervirology. 2002. — № 45. — P. — 300−307.
- Walts A. E, Thomas P. Correlation of manual screening and automated (AutoPap 300) analysisof conventional cervicovaginal smears with HPV typing using Digene HC II assay // Diagn. Cytopathol. 2003. — № 29. — P. — 256−261.
- Wang X.M., Jansen K.U., McClements W.L. DNA replicative functions of highly-expressed, codon-optimized human papillomavirus proteins El and E2. J Virol Methods. Vol. 108, № 1.-P.-83−90.
- Wang B., Amerio P., Sauder D. N. Role of cytokines in epidermal Langerhans cell migration
- J. Leukoc. Biol. 1999. — № 66. — P. — 33−39.
- Watts D.K., Koutsky L.A., Holmes K.K. et al. Low risk of perinatal transmission of human papillomavirus: result from a prospective cohort study // Am. J. Obstet. Gynecol. 1998. -№ 178.-P.-365−373.
- Werness B.A., Levine A.J., Howley P.M. Association of human papillomavirus types 16 and 18 E6 protein with p53 // Science. 1990. — № 248. — P. — 76−79.
- Weston A.C., Prolla J.C. Association between esophageal squamous cell carcinoma and human papillomavirus detected by Hybrid Capture II assay // Dis Esophagus. 2003. — № 16.-P.-224−228.
- Whitcombe D., Theaker J., Guy S.P. et al. Detection of PCR products using self-probing amplicons and fluorescence // Nat. biotechnology. 1999. — № 17. — P. — 804−807.
- Wiest T., Schwarz E., Enders C. et al. Involvement of intact HPV 16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control // Oncogene. 2002. — № 21. — P. — 1510−1517.
- Wiley D.J., Douglas J., Beutner K. et al. External genital warts: diagnosis, treatment, and prevention // Clin. Infect. Dis. 2002. — Vol. 35, № 2. — P. — 210−24.
- Wohlfahrt J., Melbye M. Age at any birth is associated with breast cancer risk // Epidemiology. 2001. -№ 12. — P. — 68−73.
- Wolf J.K., Franco E.L., Arbeit J.M. et al. Innovations in understanding the biology of cervicalcancer//Cancer.-2003. Vol. 98, № 9. — P. — 2064−2069.
- Woodworth C. D. HPV innate immunity // Front Biosci. 2002. — № 7. — P. — 2058−2071.
- Woodworth C. D., Simpson S. Comparative lymphokine secretion by cultured normal human cervical keratinocytes, papillomavirus-immortalized, and carcinoma cell lines // Am. J. Pathol. 1993. -№ 142. — P. — 1544−1555.
- Wright T.C., Sun X.W., Koulos J. Comparison of management algorithms for the evaluationof women with low-grade cytologic abnormalities // Obstet. Gynecol. 1995. — № 85. — P. -202.
- Xi L.F., Carter J.J., Galloway D.A. et al. Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students // Cancer Epidemiol. Biomarkers. Prev. 2002. — № 11. — P. — 343−351.
- Xi L. F., Koutsky L. A., Galloway D. A. et al. Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia // Journal of the National Cancer Institute. 1997. — № 89. — P. — 796−802.
- Yamada T., Manos M. M., Peto et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective // Journal of Virology. 1997. — № 71. — P. — 24 632 472.
- Zerfass K., Schulze A., Spitkovsky D. et al. Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation // J. Virol. 1995. — № 69. — P. — 6389−6399.
- Zur Hausen H. Papillomavirus infection a major cause of human cancer // Biochim. Biophys. Acta. — 1996. — № 1288. — P. — 55−78.
- Zur Hausen H. Papillomaviruses in human cancers // Proc. Assoc. Am. Physicians. 1999. -№ 111.-P.-581−587.
- Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application // Nature. 2002. -№ 2. — P. — 342−350.
- Zur Hauzen H. Viruses in human cancers // Science. 1991. — № 254. — P. — 1167−1173.